Lupin Limited has achieved a significant milestone in environmental sustainability by receiving the highest 'A' leadership rating from Climate Disclosure Project (CDP) for both Climate Change and Water Security categories. This recognition positions the global pharmaceutical company among distinguished leaders who champion sustainability and transparency at the highest level.

Exceptional Performance in ESG Ratings

The double 'A' rating demonstrates Lupin's exceptional accomplishments in climate action and water management. This achievement represents substantial enhancement compared to the company's previous performance, showcasing consistent year-over-year progress in environmental stewardship.

Comprehensive Sustainability Commitment

Lupin's outstanding ratings reflect the company's steadfast commitment to sustainability through proactive initiatives aimed at mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations. The CDP's rigorous scoring framework evaluates organizations on governance, strategy, risk management, and performance metrics related to climate and water, driving accountability and action across global markets.

Ramesh Swaminathan, Executive Director, Global CFO and Head – API Plus SBU at Lupin, emphasized the company's dedication to environmental responsibility. He highlighted how CDP's strict framework has helped shape and accelerate the company's climate initiatives, fostering ongoing progress in establishing new sustainability standards and generating lasting value for communities and the planet.

Additional ESG Recognition

Beyond the CDP achievement, Lupin has demonstrated excellence across multiple ESG evaluation platforms. The company achieved an impressive S&P Global ESG score of 91.00 in 2025, representing a best-in-class global achievement that positions Lupin among an elite group of companies worldwide surpassing the 90-point threshold.

Global Pharmaceutical Leadership

As a global pharmaceutical leader headquartered in Mumbai, India, Lupin distributes products across over 100 markets worldwide. The company specializes in pharmaceutical products including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin maintains a strong position in India and the United States across multiple therapy areas, supported by 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals.

Source:

Lupin Limited has entered into a strategic licensing and supply agreement with Galenicum Health, S.L.U. for injectable Semaglutide, marking a significant expansion of the pharmaceutical company's diabetes care portfolio across international markets.

Partnership Structure and Scope

The agreement, executed through Lupin's subsidiary Lupin Atlantis Holdings SA (LAHSA), covers finished formulations of injectable Semaglutide, a GLP-1 receptor agonist, across 23 countries globally. The partnership encompasses key markets including Canada, Europe, Southeast Asia and Latin America.

Strategic Market Positioning

Fabrice Egros, President, Corporate Development at Lupin, emphasized the partnership's significance in strengthening the company's Semaglutide portfolio. The collaboration positions Lupin to capitalize on worldwide growth opportunities in the expanding GLP-1 market, leveraging the company's extensive commercial presence across the targeted regions.

Semaglutide represents a critical therapy as diabetes continues to escalate globally and obesity emerges as a major health priority. The partnership enables Lupin to scale access to this important medication while reinforcing its commitment to delivering high-quality, cost-effective medicines.

Product Overview and Applications

Semaglutide is a generic form of glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar and appetite. The medication serves dual therapeutic purposes:

• Diabetes Management: Prescribed for adults with Type 2 Diabetes alongside diet and exercise
• Weight Management: Used for long-term weight management in adults with obesity or overweight conditions

Galenicum's Strategic Focus

Joaquim Domingo, co-founder of Galenicum, highlighted the partnership as a cornerstone of the company's strategy to scale high-impact volumes of Semaglutide globally. Galenicum has invested heavily in its GLP-1 development pipeline to meet the surging demand for these therapies, positioning itself as a leader in the B2B GLP-1 space.

The Barcelona-based company operates across more than 70 countries worldwide, maintaining a diversified portfolio across key therapeutic areas including cardiovascular, central nervous system, pain management, and anti-infectives, with particular strength in diabetes care.

Company Profiles

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. The company maintains 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by over 24,000 professionals. Lupin specializes in pharmaceutical products including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

Galenicum Health, headquartered in Esplugues de Llobregat, Barcelona, Spain, specializes in the development, manufacturing, and commercialization of generic medicines and value-added generics. The company focuses on affordability and quality, serving patients and healthcare systems across Europe, Latin America, Asia, and Africa through its state-of-the-art manufacturing facility and dedicated R&D centers.